FDA Import Alert 66-80: how to research GLP-1 bulk ingredients

01

What Import Alert 66-80 covers

Import Alert 66-80 is titled Detention Without Physical Examination of Glucagon-Like Peptide-1 Receptor Agonist Bulk Drug Substances. FDA explains that GLP-1 active pharmaceutical ingredients are drugs because they are intended to become components of drug products and are subject to current good manufacturing practice requirements.

The alert instructs FDA divisions that covered GLP-1 API shipments may be detained without physical examination unless the named manufacturer and product are on its Green List. The public page describes apparent violations and evidence a firm may submit when seeking release or Green List treatment.

The document is guidance for field personnel and does not create rights or bind the public. Read it as a current enforcement record, not a permanent catalog of every lawful or quality ingredient source.

02

What detention without physical examination means

DWPE allows FDA to detain an offered shipment based on information associated with the alert instead of first sampling or physically examining that shipment. FDA’s general import-alert page says alerts can identify products, firms, shippers, importers, countries, or other information connected to apparent violations.

Detention is not the same as a recall of a product already distributed in the United States, and an import alert is not a criminal judgment. A shipment may be supported with evidence for release, and a firm may seek removal from detention treatment by demonstrating corrective measures.

Consumers usually cannot see a clinic’s complete import record. The useful question is whether a provider or pharmacy can document the actual manufacturer and supply chain instead of displaying FDA Green List as a stand-alone badge.

03

How to read the Green List without overclaiming

The Green List identifies particular GLP-1 APIs from registered foreign manufacturers whose facilities and associated products appeared, based on FDA’s evidence review, to comply with the manufacturing issues addressed by the alert. Match both the manufacturer and product; a company name alone is not enough.

The list is not an approved-supplier list for every purpose. It does not approve a bulk ingredient or finished compounded drug, establish that every shipment will be released, or show that a pharmacy used the listed source. It does not replace ingredient eligibility rules under 503A or 503B.

Record the date and preserve the row you relied on because FDA updates import-alert databases in real time. A supplier may be added, removed, or appear under another alert for different facts.

• →Match legal manufacturer name and location.
• →Match the exact API named in the Green List.
• →Record the alert version and access date.
• →Look for related warning letters, recalls, or alerts.
• →Do not convert status into an FDA-approved claim.

04

What the 2026 Harbin warning letter shows

FDA’s May 2026 warning letter to Harbin Jixianglong Biotech illustrates why source identity matters. FDA stated that the firm had been placed on the Green List based on prior quality information but purchased semaglutide API from a facility not on that list, relabeled it as manufactured by the named firm, and shipped it to the United States.

The letter says FDA recommended that the firm consider removing two relabeled batches from distribution; the firm agreed to and then initiated a voluntary recall. FDA also removed the firm from the Green List and placed it under another import alert. Those are FDA’s findings and actions in the dated record, and the firm had an opportunity to respond.

The lesson is not that every ingredient from a country or every compounded GLP-1 is affected. It is that a familiar manufacturer name on paperwork may not establish the true manufacturing source. Lot-level traceability and chronology matter.

05

Keep import status separate from compounding and shortage rules

An imported API can clear one import-related concern and still face other federal restrictions. Section 503A generally uses a patient-specific prescription framework and includes ingredient and copy restrictions. A 503B outsourcing facility has different conditions, including limits on bulk-substance use and products that are essentially copies of approved drugs.

FDA’s April 2026 clarification stated that semaglutide and tirzepatide were not on the 503B Bulks List or drug-shortage list at that time. Green List status would not override those facts. Likewise, shortage status does not approve an ingredient or excuse manufacturing problems.

Verify active ingredient, chemical form, current shortage status, 503A or 503B pathway, copy analysis, and import source as separate fields. One favorable field cannot answer the others.

06

A consumer workflow for an ingredient-source claim

Ask the dispensing pharmacy—not only the telehealth platform—for the legal manufacturer of the active ingredient and the source supporting the claim. Compare the exact name and product with the current alert. If the pharmacy will not disclose the source, record it as unknown rather than inferring Green List use.

Compare the pharmacy name on the label with state licensing records and any 503B registration claim. Check warning letters, recalls, and inspections separately. A provider’s contract with a pharmacy does not show which facility compounded a particular lot.

Do not change or stop prescribed medicine based only on an import-alert article. Discuss a product-specific concern with the prescriber and pharmacist. For a suspected quality problem or adverse event, preserve the label, packaging, lot, shipping materials, and chronology.